Expiration date: 05/2025

Structure and Composition: 

Cream 1%. 100 g contains 1 g of bifonazole

Excipients: polyethylene 400 polyethylene polypropylene glycol 4000?

in tubes of 30 g in a box 1 tube.

Characteristic:

Cream 1% - from colorless to grayish hue to colorless to grayish-cream color shade.

Description of the pharmacological actions:

Active against Trichophyton spp., Microsporum spp., Epidermophyton spp., Aspergillus spp., Corynebacterium spp., Candida albicans, Candida spp. and Malassezia furfur.

Clinical Pharmacology:

It penetrates deep into the skin, while retaining a high concentration for 48-72 hours (to allow the use Bifosin 1 times a day).

Indications:

Dermatophytosis (mikrosporiya, trihofitia, rubrofitii) candidiasis the skin of nail ridges, nails, genitals erythrasma, interdigital diaper rash, hyperhidrosis feet.

Contraindications:

Hypersensitivity.

Side effect:

Allergic reactions.

Dosage and administration:

Outwardly, cream or solution is applied to lesions thin layer, gently rubbing, 1-2 times per day. In the presence of exudative lesions, treatment begins with the application of the solution after the reduction of acute inflammation using a cream, then apply powder. The duration of treatment with rubrofitii - 2-5 weeks, microsporia smooth skin - 2 weeks, with a smooth skin lesions and external genital organs - 2-4 weeks, nail ridges and nails - at least 3-4 months, with pityriasis versicolor, erythrasma - 3 -4 weeks, with hyperhidrosis feet (powder use) - 2-3 weeks.

After the liquidation of clinical manifestations of mycosis treatment should be continued for 10-15 days, applying cream, solution or powder 1 time per day for relapse prevention.

Spray for external application of 1% as a clear, colorless or lightly colored liquid.

1 ml contains 10 mg bifonazole

Excipients: propylene - 0.3 ml of isopropanol - 0.4 ml, macrogol (polyethylene 400) - 1 ml.

20 ml - vials plastic (1) with a spray - packs cardboard.

Clinico-pharmacological group: Antifungal agents for external use

Pharmaco-therapeutic group: Antifungal

Testimony

Treatment of skin lesions caused by dermatophytes, yeast, fungi, and Malassezia furfur and Corynebacterium minutissimum:

• Mycoses of the feet and hands,
  
• Ringworm smooth skin,
  
• Pityriasis versicolor,
  
• Superficial skin candidiasis,
  
• Erythrasma,
  
• Ringworm of the scalp (powder for external use, solution for outdoor applications, a spray for external use).
  

Dosage

The drug should be used 1 time / day, at night.

Cream for external use powder for external use or topical solution applied in a thin layer on the affected skin and rub thoroughly.

Spray for external use to the affected area was sprayed in an amount sufficient for a thorough wetting and, moreover, is applied to the surrounding diseased sites as well as intact skin.

To plot the size of a palm is usually sufficient strip length 0.5-1 cm of cream or a few drops of the solution (approximately 3 mL).

To achieve a satisfactory result, the treatment should be continuous and continued during the following periods recommended: primikozah feet and interdigital spaces feet - 3-4 weeks, pridermatomikozah smooth skin - 2-3 weeks, when the surface of the skin candidiasis - 2-4 weeks, when otrubevidnom zoster, erythrasma - 2 weeks, in tinea capitis - 4 weeks.

After the disappearance of the clinical manifestations of mycosis Bifosin® continue to apply for the purpose of prevention of relapse using the drug 1 times / day for 2 weeks.

Spray for external use, a topical solution and powder for external application are preferred for the treatment of tinea capitis.

Side effect

Local reactions: redness, skin irritation, burning sensation, allergic reactions, eczema, pruritus, rash vesicular, maceration, peeling, redness, very rarely - the development of atopic dermatitis.

Side effects are reversible and disappear after cessation of therapy.

Contraindications

• Lactation (breast-feeding)
  
• Hypersensitivity to the drug.
  

Precautions: infants (under 1 year), pregnancy (I term).

Pregnancy and breast-feeding

These studies show that the drug does not appear to have any adverse effect on the mother and fetus.

Use of the drug in the I trimester of pregnancy is possible only under strict indications. In II and III trimester of pregnancy, the drug is used according to the testimony, because the drug is used topically and has no systemic action.

During the period of lactation should stop breastfeeding.

Use in children

Application Bifosina in infants is possible only under the close supervision of a physician.

Precautions: infants (under 1 year).

Special instructions

In the absence or lack of effectiveness should further examine the patient (the state of immunity, blood, endocrine system, microcirculation lesion area) and adjust the treatment in accordance with the results of the survey.

Avoid contact with the eyes of the drug.

Use in pediatrics.

Use in infants (under 1 year) is possible only under medical supervision.

Effects on ability to drive vehicles and management mechanisms

The drug has no effect on the ability to drive vehicles, machinery and other hazardous occupation activities that require special attention and fast reactions.

Overdose

The extremely low systemic absorption of the drug in the external application makes it virtually impossible overdose.

Drug interactions

The drug can be used in conjunction with other drugs, since no drug interaction reactions have been identified.